Jennifer Balliet Sells 13,000 Shares of NeoGenomics (NEO) Stock

NeoGenomics (NASDAQ:NEO) VP Jennifer Balliet sold 13,000 shares of the company’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $11.24, for a total transaction of $146,120.00. Following the completion of the sale, the vice president now owns 13,000 shares in the company, valued at approximately $146,120. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of NASDAQ NEO opened at $11.24 on Friday. The company has a market capitalization of $910.97 million, a PE ratio of 187.33, a PEG ratio of 6.28 and a beta of 0.41. NeoGenomics has a 52-week low of $7.08 and a 52-week high of $11.63. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.85 and a current ratio of 2.03.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, May 1st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. The firm had revenue of $63.40 million for the quarter, compared to the consensus estimate of $62.31 million. NeoGenomics had a negative net margin of 0.86% and a positive return on equity of 3.19%. The business’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.03 earnings per share. research analysts anticipate that NeoGenomics will post 0.09 earnings per share for the current year.

A number of equities research analysts have weighed in on NEO shares. Canaccord Genuity upped their price objective on shares of NeoGenomics from $23.00 to $24.00 in a report on Tuesday, March 13th. BidaskClub upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. ValuEngine upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Tuesday, April 17th. First Analysis cut shares of NeoGenomics from an “overweight” rating to an “equal weight” rating and set a $11.00 price objective on the stock. in a report on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Thursday, March 1st. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $16.50.

Several hedge funds and other institutional investors have recently modified their holdings of NEO. First Light Asset Management LLC lifted its stake in shares of NeoGenomics by 23.7% in the first quarter. First Light Asset Management LLC now owns 4,760,332 shares of the medical research company’s stock worth $38,844,000 after buying an additional 912,730 shares in the last quarter. Franklin Resources Inc. lifted its position in NeoGenomics by 101.5% during the first quarter. Franklin Resources Inc. now owns 1,557,393 shares of the medical research company’s stock valued at $12,708,000 after purchasing an additional 784,493 shares during the period. Gabelli Funds LLC lifted its position in NeoGenomics by 61.2% during the first quarter. Gabelli Funds LLC now owns 768,000 shares of the medical research company’s stock valued at $6,267,000 after purchasing an additional 291,600 shares during the period. Fairpointe Capital LLC bought a new position in NeoGenomics during the fourth quarter valued at approximately $2,464,000. Finally, RMB Capital Management LLC lifted its position in NeoGenomics by 50.0% during the first quarter. RMB Capital Management LLC now owns 808,306 shares of the medical research company’s stock valued at $6,596,000 after purchasing an additional 269,414 shares during the period. Hedge funds and other institutional investors own 82.24% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply